PMID- 21826030
OWN - NLM
STAT- MEDLINE
DCOM- 20120516
LR  - 20120119
IS  - 1524-4040 (Electronic)
IS  - 0148-396X (Linking)
VI  - 70
IP  - 2
DP  - 2012 Feb
TI  - Reported antiplatelet use influences long-term outcome independently in deep 
      intracerebral hemorrhage.
PG  - 342-50; discussion 350
LID - 10.1227/NEU.0b013e3182311266 [doi]
AB  - BACKGROUND: Recent studies have focused on antiplatelet (AP) use in intracerebral 
      hemorrhage (ICH) patients. Several outcome predictors have been debated, but 
      influences on mortality and outcome still remain controversial, especially for 
      different ICH locations. OBJECTIVE: To investigate the characteristics and 
      functional outcome of ICH patients with reported regular AP use according to 
      hemorrhage locations. METHODS: This retrospective analysis included 210 
      consecutive spontaneous ICH patients. Clinical data including the preadmission 
      status, initial presentation, neuroradiological data, treatment, and outcome were 
      evaluated. Analyses were calculated for AP use vs non-AP use according to 
      hematoma locations, and multivariate models were calculated for hematoma 
      expansion and unfavorable (modified Rankin Scale = 4-6) long-term functional 
      outcome (at 1 year). RESULTS: For all AP users ICH volume was significantly 
      larger, 27.7 mL (interquartile range 7.4-66.1) vs 16.8 mL (interquartile range 
      4.2-44.7); (P = .032). Analyses showed an increased mortality for AP users at 90 
      days and 1 year (P = .036; P = .008). Multivariately, for all ICH patients, prior 
      AP use was independently associated with hematoma expansion (odds ratio [OR] 
      3.61; P = .026) and poorer functional outcome at 1 year (OR 3.82, P = .035). In 
      deep ICH patients, AP use was an independent predictor of an unfavorable 
      functional outcome at 1 year (OR 4.75, P = .048). CONCLUSION: Hematoma expansion 
      and more frequent unfavorable long-term functional outcome were independently 
      associated with prior AP use for all patients, and in deep ICH patients AP use 
      was an independent predictor of an unfavorable long-term functional outcome.
FAU - Kuramatsu, Joji B
AU  - Kuramatsu JB
AD  - Department of Neurology, University of Erlangen, Erlangen, Germany. 
      Joji.Kuramatsu@uk-erlangen.de
FAU - Mauer, Christoph
AU  - Mauer C
FAU - Kiphuth, Ines-Christine
AU  - Kiphuth IC
FAU - Lucking, Hannes
AU  - Lucking H
FAU - Kloska, Stephan P
AU  - Kloska SP
FAU - Kohrmann, Martin
AU  - Kohrmann M
FAU - Huttner, Hagen B
AU  - Huttner HB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
MH  - Aged
MH  - Cerebral Hemorrhage/*complications/*pathology
MH  - Female
MH  - Humans
MH  - Male
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Recovery of Function/*drug effects
MH  - Retrospective Studies
EDAT- 2011/08/10 06:00
MHDA- 2012/05/17 06:00
CRDT- 2011/08/10 06:00
PHST- 2011/08/10 06:00 [entrez]
PHST- 2011/08/10 06:00 [pubmed]
PHST- 2012/05/17 06:00 [medline]
AID - 10.1227/NEU.0b013e3182311266 [doi]
PST - ppublish
SO  - Neurosurgery. 2012 Feb;70(2):342-50; discussion 350. doi: 
      10.1227/NEU.0b013e3182311266.